E
PTGX icon

Ergoteles’s Protagonist Therapeutics PTGX Stock Holding History

Ergoteles’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,000
Closed -$251K – 1667
2022
Q4 		$251K Sell
23,000
-6,530
-22% -$55.1K 0.01% 979
2022
Q3 		$249K Buy
+29,530
New +$279K 0.01% 1075
2021
Q1 		– Sell
-11,700
Closed -$236K – 1008
2020
Q4 		$236K Buy
+11,700
New +$252K 0.01% 573

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ergoteles's PTGX Position: Q1 2023 in Review

Ergoteles sold out of Protagonist Therapeutics (PTGX) in Q1 2023, closing a stake of 23,000 shares — an estimated $251K sold.

Ergoteles first reported a position in PTGX in Q4 2020 and held it in 3 quarters. The position peaked at $251K in Q4 2022. 137 funds tracked by Wall St. Rank hold PTGX as of Q1 2023.

  • Ergoteles reported no remaining Protagonist Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 23,000 Protagonist Therapeutics shares in Q1 2023, an estimated $251K.
  • Ergoteles first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 3 quarters.
  • Ergoteles's Protagonist Therapeutics position peaked at $251K in Q4 2022.
  • 137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.